Fludarabine and bendamustine in refractory and relapsed indolent lymphoma--a multicenter phase I/II Trial of the east german society of hematology and oncology (OSHO)

Leukemia & Lymphoma
Michael KoenigsmannA Franke

Abstract

The therapy of patients with relapsed or refractory indolent lymphoma relies on the development of new drug combinations. The drugs bendamustine and fludarabine have cytotoxic activity as monotherapy in indolent lymphoma and show synergism in vitro. In this study, we combined both drugs in a multicenter clinical phase I/II trial to evaluate their toxicity and efficacy. Bendamustine was given at 30 or 40 mg/m2/d (dose levels 1 and 2), fludarabine at 30 mg/m2/d, each drug on days 1 to 3. Six cycles were to be given every 4 weeks. A total of 29 patients with relapsed or refractory indolent lymphoma were included in the study. During phase I, 9 patients were treated at dose level 1 and 7 patients at dose level 2. Thirteen patients were added to the study during phase II. Fourteen patients had follicular lymphoma, 11 patients mantle cell lymphoma, 2 patients lymphoplasmocytic and 2 patients nodal marginal zone lymphoma. Median age was 62 years (range 39-74). All patients were in stages III or IV of their disease and had received prior chemotherapy with or without additional radio- or immunotherapy. The dose limiting toxicity was hematotoxicity in all cases and occurred in 3 of 7 evaluable patients at dose level I and in 3 of 7 patie...Continue Reading

References

Aug 15, 2000·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P SchöffskiA Ganser
Feb 24, 2001·Journal of Cancer Research and Clinical Oncology·R KathK Höffken
Mar 21, 2001·Deutsche medizinische Wochenschrift·R KathK Höffken
Feb 28, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J S WhelanA M Cassoni
May 23, 2002·Seminars in Oncology·Rafael Rosell, Lucio Crinó
Jun 14, 2002·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Vincent GrégoirePierre Scalliet
Jul 3, 2002·Seminars in Oncology·Volker Heinemann
Aug 10, 2002·Seminars in Oncology·Wolfram Pönisch, Dietger Niederwieser
Aug 10, 2002·Seminars in Oncology·Mathias J RummelDieter Hoelzer
Aug 16, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E WeidmannP S Mitrou

❮ Previous
Next ❯

Citations

Apr 9, 2010·Cancer Chemotherapy and Pharmacology·Nishant Tageja, Jasdeepa Nagi
Aug 12, 2005·Current Opinion in Oncology·Michael E Williams, John J Densmore
Jan 1, 2009·Cancer Management and Research·Ibrahim T AldossPhilip J Bierman
Jan 1, 2009·OncoTargets and Therapy·Fredrick Hagemeister, George Manoukian
Jun 4, 2008·Future Oncology·Christos ApostolopoulosGeorgios Giamas
Jun 23, 2011·Clinical Medicine Insights. Oncology·Nishant Tageja
Aug 23, 2008·Journal of Cancer Research and Clinical Oncology·M Schmidt-HieberI W Blau
Nov 5, 2013·Leukemia & Lymphoma·Enrico DerenziniBruce D Cheson
Sep 29, 2015·Expert Review of Anticancer Therapy·Sara SteffanoniAlden Moccia
Jun 6, 2012·Expert Opinion on Pharmacotherapy·Julie Elizabeth Chang, Brad Steven Kahl
May 6, 2011·Seminars in Hematology·Mathias J Rummel, Stephanie A Gregory
Nov 1, 2008·Clinical Lymphoma & Myeloma·Mathias Rummel
Mar 8, 2008·Clinical Lymphoma & Myeloma·Andres Forero-Torres, Mansoor N Saleh
Feb 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D Cheson, Mathias J Rummel
Jan 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jonathan W FriedbergBruce D Cheson
Sep 14, 2012·The Cochrane Database of Systematic Reviews·Liat VidalOfer Shpilberg
Aug 1, 2020·The Cancer Journal·Francesco BertoniEmanuele Zucca
Sep 15, 2010·Expert Review of Anticancer Therapy·Chaitra Ujjani, Bruce D Cheson

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.